U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C18H14ClFN2O3
Molecular Weight 360.767
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETHYL LOFLAZEPATE

SMILES

CCOC(=O)C1N=C(C2=CC=CC=C2F)C3=C(NC1=O)C=CC(Cl)=C3

InChI

InChIKey=CUCHJCMWNFEYOM-UHFFFAOYSA-N
InChI=1S/C18H14ClFN2O3/c1-2-25-18(24)16-17(23)21-14-8-7-10(19)9-12(14)15(22-16)11-5-3-4-6-13(11)20/h3-9,16H,2H2,1H3,(H,21,23)

HIDE SMILES / InChI

Molecular Formula C18H14ClFN2O3
Molecular Weight 360.767
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including http://meds.famguerra.com/?pagina=36557.htm https://www.ncbi.nlm.nih.gov/pubmed/2861304 https://www.ncbi.nlm.nih.gov/pubmed/2866771

Ethyl loflazepate (Lof) has been used widely as a sedative and anxiolytic agent for nearly 20 years. Ethyl loflazepate was designed to be a prodrug for descarboxyloflazepate, its active metabolite. It is the active metabolite which is responsible for most of the pharmacological effects rather than ethyl loflazepate. The main metabolites of ethyl loflazepate are descarbethoxyloflazepate, loflazepate and 3-ydroxydescarbethoxyloflazepate which are the benzodiazepine receptor agonists. Ethyl loflazeplate is commercialized in Mexico, under the trade name Victan. It is officially approved for the following conditions Anxiety: Post-trauma anxiety; Anxiety associated with severe neuropathic pain; Generalized anxiety disorder (GAD); Panic attack; Delirium tremens. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Accumulation of the active metabolites of ethyl loflazepate are not affected by those with renal failure or impairment. The symptoms of an overdose of ethyl loflazepate include sleepiness, agitation and ataxia. Hypotonia may also occur in severe cases. These symptoms occur much more frequently and severely in children. High doses of the antidepressant fluvoxamine may potentiate the adverse effects of ethyl loflazepate.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
The biochemical study of intermaxillary fixation (IMF) stress in oral surgery inpatients.
2001
Specific and sensitive analysis of nefopam and its main metabolite desmethyl-nefopam in human plasma by liquid chromatography-ion trap tandem mass spectrometry.
2006 Nov 16
Group cognitive behavior therapy for Japanese patients with social anxiety disorder: preliminary outcomes and their predictors.
2007 Dec 10
Intractable depression successfully treated with a combination of autogenic training and high-dose antidepressant in department of otorhinolaryngology: a case report.
2009 Aug 14
Selection of adequate optimization criteria in chromatographic separations.
2009 Jul
[Lymphocytic colitis probably due to etifoxine. A case with relapse after reintroduction].
2009 Mar-Apr
Benzodiazepine prescription and length of hospital stay at a Japanese university hospital.
2009 Oct 9
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010 Dec
Pregnancy in woman with spinal cord stimulator for complex regional pain syndrome: a case report and review of the literature.
2010 Dec
New and emerging therapeutic agents for the treatment of fibromyalgia: an update.
2010 Jul 22
Effects of etizolam and ethyl loflazepate on the P300 event-related potential in healthy subjects.
2010 Nov 3
Change in quality of life and their predictors in the long-term follow-up after group cognitive behavioral therapy for social anxiety disorder: a prospective cohort study.
2010 Oct 14
Patents

Sample Use Guides

½ to 1½ tablet at day (1 ime or several tomes at day).
Route of Administration: Oral
In Vitro Use Guide
CM6912 (ethyl loflazepate ) inhibited the specific binding of 3H-diazepam by 25%, 75% and 90% at concentrations of 0.01 microM, 0.1 microM and 1 microM, respectively to the synaptosomal membrane fraction of rat cerebrum.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:28:45 GMT 2023
Edited
by admin
on Fri Dec 15 16:28:45 GMT 2023
Record UNII
VJB5FW9W9J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ETHYL LOFLAZEPATE
INN   JAN   MART.   MI   WHO-DD  
INN  
Official Name English
ETHYL 7-CHLORO-5-(O-FLUOROPHENYL)-2,3-DIHYDRO-2-OXO-1H-1,4-BENZODIAZEPINE-3-CARBOXYLATE
Common Name English
MEILAX
Brand Name English
ETHYL LOFLAZEPATE [JAN]
Common Name English
ethyl loflazepate [INN]
Common Name English
ETHYL LOFLAZEPATE [MART.]
Common Name English
Ethyl loflazepate [WHO-DD]
Common Name English
ETHYL LOFLAZEPATE [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1012
Created by admin on Fri Dec 15 16:28:45 GMT 2023 , Edited by admin on Fri Dec 15 16:28:45 GMT 2023
WHO-VATC QN05BA18
Created by admin on Fri Dec 15 16:28:45 GMT 2023 , Edited by admin on Fri Dec 15 16:28:45 GMT 2023
DEA NO. 2758
Created by admin on Fri Dec 15 16:28:45 GMT 2023 , Edited by admin on Fri Dec 15 16:28:45 GMT 2023
WHO-ATC N05BA18
Created by admin on Fri Dec 15 16:28:45 GMT 2023 , Edited by admin on Fri Dec 15 16:28:45 GMT 2023
Code System Code Type Description
MESH
C029617
Created by admin on Fri Dec 15 16:28:45 GMT 2023 , Edited by admin on Fri Dec 15 16:28:45 GMT 2023
PRIMARY
DRUG CENTRAL
1092
Created by admin on Fri Dec 15 16:28:45 GMT 2023 , Edited by admin on Fri Dec 15 16:28:45 GMT 2023
PRIMARY
MERCK INDEX
m5146
Created by admin on Fri Dec 15 16:28:45 GMT 2023 , Edited by admin on Fri Dec 15 16:28:45 GMT 2023
PRIMARY Merck Index
PUBCHEM
3299
Created by admin on Fri Dec 15 16:28:45 GMT 2023 , Edited by admin on Fri Dec 15 16:28:45 GMT 2023
PRIMARY
NCI_THESAURUS
C65566
Created by admin on Fri Dec 15 16:28:45 GMT 2023 , Edited by admin on Fri Dec 15 16:28:45 GMT 2023
PRIMARY
EPA CompTox
DTXSID60865475
Created by admin on Fri Dec 15 16:28:45 GMT 2023 , Edited by admin on Fri Dec 15 16:28:45 GMT 2023
PRIMARY
RXCUI
24524
Created by admin on Fri Dec 15 16:28:45 GMT 2023 , Edited by admin on Fri Dec 15 16:28:45 GMT 2023
PRIMARY RxNorm
EVMPD
SUB07290MIG
Created by admin on Fri Dec 15 16:28:45 GMT 2023 , Edited by admin on Fri Dec 15 16:28:45 GMT 2023
PRIMARY
WIKIPEDIA
ETHYL LOFLAZEPATE
Created by admin on Fri Dec 15 16:28:45 GMT 2023 , Edited by admin on Fri Dec 15 16:28:45 GMT 2023
PRIMARY
FDA UNII
VJB5FW9W9J
Created by admin on Fri Dec 15 16:28:45 GMT 2023 , Edited by admin on Fri Dec 15 16:28:45 GMT 2023
PRIMARY
INN
4837
Created by admin on Fri Dec 15 16:28:45 GMT 2023 , Edited by admin on Fri Dec 15 16:28:45 GMT 2023
PRIMARY
SMS_ID
100000090254
Created by admin on Fri Dec 15 16:28:45 GMT 2023 , Edited by admin on Fri Dec 15 16:28:45 GMT 2023
PRIMARY
ECHA (EC/EINECS)
249-489-4
Created by admin on Fri Dec 15 16:28:45 GMT 2023 , Edited by admin on Fri Dec 15 16:28:45 GMT 2023
PRIMARY
DRUG BANK
DB01545
Created by admin on Fri Dec 15 16:28:45 GMT 2023 , Edited by admin on Fri Dec 15 16:28:45 GMT 2023
PRIMARY
CAS
29177-84-2
Created by admin on Fri Dec 15 16:28:45 GMT 2023 , Edited by admin on Fri Dec 15 16:28:45 GMT 2023
PRIMARY
ChEMBL
CHEMBL1213460
Created by admin on Fri Dec 15 16:28:45 GMT 2023 , Edited by admin on Fri Dec 15 16:28:45 GMT 2023
PRIMARY
Related Record Type Details
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
Related Record Type Details
METABOLITE ACTIVE -> PARENT
Related Record Type Details
ACTIVE MOIETY